<DOC>
	<DOCNO>NCT02552901</DOCNO>
	<brief_summary>Performance evaluation LFT Dye Monitor System use ICG - plasma disappearance rate value ( PDR ) ass liver function normal patient well patient mild severe hepatic impairment compare manual Serum ICG PDR .</brief_summary>
	<brief_title>Cardiox Liver Function Test Pivotal Trial</brief_title>
	<detailed_description>Indocyanine green ( ICG ) water-soluble , non-toxic tricarbocyanine dye , extract principally hepatic parenchymal cell excrete almost entirely bile without enterohepatic circulation . Clinically , elimination rate use primarily measure hepatic function liver blood flow . ICG study also use ophthalmic angiography determination cardiac output . Beginning 1959 , first human clinical study report wherein indocyanine green ( ICG ) bolus injected vein , blood sample withdraw period time analyzed ICG concentration . This method refer hereinafter serial blood sample method . These blood sample send clinical laboratory multi-step process centrifuging , separation spectrophotometric measurement ICG level . The laboratory-based measured level residual ICG level use determine ICG clearance rate R15 value residual amount dye remain 15 minute , express percentage initial concentration . As alternative time- labor-consuming serial blood sample method , non-invasive technique first report nearly 20 year ago . In first publish clinical study , Ishigami report use pulse dye densitometry ( PDD ) method transcutaneously detect rate clearance ICG bloodstream refer hereinafter dynamic liver function test . PDD express ICG elimination term indocyanine green plasma disappearance rate relative ICG concentration change assess . The result noninvasive method show correlate obtain invasive method use critically ill patient ( hemodynamically unstable stable ) , patient liver surgery . ICG elimination rate liver transplantation measure either invasive noninvasive ICG method widely use evaluate graft function . Studies show ICG elimination , measure day transplantation , reflect graft function use predict graft viability expect survival patient . Sequential measurement ICG elimination day 0 28 transplantation , show predict clinical outcome early postoperative period live donor transplantation . All study show ICG elimination rate accurate test evaluate liver dysfunction , lack ability differentiate underlying cause hepatic dysfunction . Unlike currently exist PDD method perform liver function testing , LFT Dye Monitor System employ sensitive method transcutaneous measurement ICG concentration level blood use NIR fluorescence , sensor attach loosely scaphoid fossa ear . Thus , chemical property ICG dye fluoresce properly excite use LFT system enable much low concentration ICG detectable .</detailed_description>
	<mesh_term>Liver Failure</mesh_term>
	<criteria>1 . Male female 18 75 year age inclusive , time Screening . 2 . Voluntarily provide write informed consent . 3 . Female patient eligible follow apply : Not pregnant ( negative urine pregnancy test Screening visit ) ; Not lactate ; Not plan become pregnant within duration study ; Surgically sterile , least 2 year postmenopausal , practice acceptable form birth control ( define use intrauterine device , barrier method spermicide , condom , subdermal implant , oral contraceptive , abstinence , sterilization monogamous partner ) great 60 day prior Screening commits use acceptable form birth control duration study . 4 . If healthy volunteer ; consider generally good health , opinion Investigator , Screening visit base upon result medical surgical history , vital sign , physical examination , clinical laboratory test . 5 . Prior receive ICG injection subject agree fast least eight ( 8 ) hour . 6 . If subject liver cirrhosis ; consider general satisfactory health , opinion Investigator ( hepatic impairment ) Screening visit base upon result medical surgical history , vital sign , physical examination , nonhepatic clinical laboratory test . 7 . Liver cirrhosis subject must clinical diagnosis hepatic impairment base documented evidence hepatic cirrhosis medical history , previous liver biopsy , hepatic ultrasound ; conforms criteria class A B C ChildsPugh classification ( Appendix B ) ; expect require ICG liver function study , liver transplantation , liver resection , liver cirrhosis prognosis evaluation , functional liver cell mass and/or general liver dysfunction evaluation . 8 . On stable drug therapy expect change ( i.e . dose , frequency , addition deletion agent ) least 2 week ICG dye injection . 9 . Must , Investigator 's opinion , able comply study procedure . 10 . If Subject enrol fifth group diagnosis acute liver failure ( ALF ) define Principal Investigator . 1 . Have clinically significant condition unstable current illness would , opinion Investigator , preclude study participation interfere assessment procedure ; 2 . Known allergy sensitivity ICG dye history allergy iodide ; 3 . Actively bleed associate acute blood volume change .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>hepatic</keyword>
	<keyword>liver</keyword>
	<keyword>LFT</keyword>
	<keyword>hepatic assessment</keyword>
	<keyword>ICG dye</keyword>
	<keyword>indocyanine green dye</keyword>
	<keyword>Diagnostic Green</keyword>
	<keyword>Pulsion</keyword>
	<keyword>Akorn</keyword>
	<keyword>Cardiox</keyword>
	<keyword>anazen</keyword>
	<keyword>essence</keyword>
	<keyword>dye detection monitor</keyword>
	<keyword>Earpads</keyword>
	<keyword>flow sensor</keyword>
	<keyword>scaphoid fossa</keyword>
	<keyword>liver disease</keyword>
	<keyword>acute hepatic failure</keyword>
	<keyword>AHF</keyword>
	<keyword>NASH</keyword>
	<keyword>hepatitis C</keyword>
	<keyword>cirrhosis</keyword>
	<keyword>MELD</keyword>
	<keyword>pulse dye densitometry</keyword>
	<keyword>liver transplant</keyword>
	<keyword>fluorescence</keyword>
	<keyword>near infra-red</keyword>
	<keyword>serial blood draw</keyword>
	<keyword>PDR</keyword>
	<keyword>plasma disappearance rate</keyword>
	<keyword>R15</keyword>
	<keyword>k coefficient</keyword>
	<keyword>transcutaneously</keyword>
	<keyword>liver donor</keyword>
	<keyword>liver dysfunction</keyword>
	<keyword>Child-Pugh</keyword>
	<keyword>AST</keyword>
	<keyword>ALT</keyword>
	<keyword>GGT</keyword>
	<keyword>alk phos</keyword>
	<keyword>prothrombin time</keyword>
	<keyword>albumin</keyword>
	<keyword>serum ICG</keyword>
	<keyword>liver function test</keyword>
</DOC>